NEWS!!!!!!!!
It's official on our Big Fish on the BOD
Smitter SMTT
Computer Vision Systems Laboratories Corp. Announces the Appointment of Douglas Miscoll to Its Board of Directors
PrintAlert
Computer Vis Sys Lab (OTCBB:CVSL)
Intraday Stock Chart
Today : Tuesday 13 March 2012
Computer Vision Systems Laboratories Corp. (OTCBB:CVSL), a niche medical device company, announced today that its Board of Directors appointed Douglas Miscoll, as Director of the Company, effective March 7, 2012.
"I'm delighted to welcome Doug to our Board of Directors," said Thomas DiCicco, President and Chief Executive Officer of Computer Vision Systems Labs. "His background of successful executive leadership in the worldwide private and public finance sectors, combined with his extensive Board experience, make him a strong addition to the CVSL Board as we pursue our global growth strategy."
Mr. Doug Miscoll is the Chief Investment Officer of Ravello Partners LLC, a private asset management firm. Prior to founding Ravello, Mr. Miscoll was a Managing Director at Newlight Management, where he was responsible for managing all aspects of two private equity funds and a hedge fund with assets over $135 million focused on investments in technology, media and communications companies. He originated and directed the firm's public market investment activities. He served as Director or Observer of multiple private portfolio companies including CareGain (sold to Fiserve), Massive (sold to Microsoft) and VitalStream (sold to Internap). Mr. Miscoll was a member of an investment group that acquired control of Laidlaw & Co. in 1996. He helped restructure the firm and was instrumental in its return to profitability, resulting in a profitable sale. Previously, he was a Managing Director of Northgate Ventures, a venture capital fund focused on early stage investments in technology companies. Mr. Miscoll was a founding member of the management team that created K-III Communications, a leveraged build-up in the media, publishing and information services industries sponsored by Kohlberg Kravis Roberts & Co. Mr. Miscoll received a MBA from Georgetown University, a Graduate Certificate from Templeton College, Oxford University, and a BA from Santa Clara University. He serves on the Board of Directors of Raketu Inc.
About the Sentinel BreastScan™
The Sentinel BreastScan is an advanced non-invasive infrared breast imaging system used as an adjunctive modality by doctors specializing in breast imaging and breast cancer treatment. Utilizing infrared imaging and proprietary software employing artificial intelligence techniques, Sentinel BreastScan™ is designed to be used as an adjunctive test with mammography, ultrasound or clinical examination for the early detection of breast cancer. It is an FDA-510k cleared, non-invasive touchless procedure offered to women of any age, to help determine current breast health. Test results are immediately available in the form of a fully-interpreted, objective report, to assist in the doctor's determination of breast health.
We also plan to expand the role of our infrared imaging technology, in accordance with our FDA 510k, "indications for use" and devote R&D resources to the detection of skin cancer. Skin cancer has no approved imaging modalities and is detected by visual observation by a dermatologist followed by subsequent biopsy of suspicious lesions. Our early research has shown the ability of our technology to detect certain invisible skin cancers.
About the Maneuverable Guidewire
This guidewire (US Patent 7,141,024 Nov 28, 2006) is unique, easy to use, and intended for use in all PTCA procedures. The maneuverable coiled guidewire is based on the "Buckling" theory in which the tip is bent according to the force applied to it. It is made of a high grade stainless steel PTFE (Teflon) coated coil and a thin wire disposed in it. The distal end of the coil is treated in such a way that when the inner wire is pulled the distal tip buckles and bends accordingly. This feature is designed to allow the doctor to easily maneuver through the most tortuous vessels. CVSL plans to aggressively seek strategic partners through licensing agreements and joint ventures to manufacture and/or distribute the guidewire.
About Computer Vision Systems Laboratories
Computer Vision Systems Laboratories Corp, is currently traded on the OTC BB and OTCQB under the symbol CVSL. Computer Vision Systems Laboratories Corp, formerly Cardio Vascular Medical Device Corp. is a development-stage company. Computer Vision Systems Laboratories has obtained the worldwide exclusive license for the FDA cleared Sentinel BreastScan which focuses on early detection of breast cancer. Additionally, the company is focused on licensing, partnering, manufacturing and / or distributing our patented breakthrough maneuverable-coiled guidewire. CVSL will seek strategic partners in the industry with which it will promote its guidewire product. Parties interested in discussing the guidewire, Sentinel BreastScan, or investment opportunities may contact the CEO at thomasdicicco@CVSLAB.com.
